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 Antimicrobial resistance (AMR) is the ability of a microorganism to survive treatment 
with an antibiotic or antimicrobial agent to which it was previously sensitive. Resistant bacteria 
are able to withstand the attack of antimicrobials, so that standard treatments become ineffective 
and infections persist and may spread to others. The rapid spread of AMR is a serious problem 
for the treatment of bacterial infections and increase the costs of therapy. The O’Neill report 
estimates that by 2050 10 million lives and 100 trillion USD of economic output are at risk 
from AMR.  
 Bacteria have evolved different mechanisms to prevent the harmful effect of 
antibacterial drugs and one of the most important mechanism is the increased expression of 
efflux pumps (EPs) that are able to export different classes of antimicrobial agents outside the 
bacterium before they reach their targets within the bacterial cell. EPs also play a role in biofilm 
formation and quorum sensing (QS) process. In bacteria the QS is a cell-to-cell communication 
and regulatory mechanism that controls gene expression depending on bacterial cell density. 
Bacterial biofilm is a microbial community consisting of sessile bacterial cells attached to each 
other and to a surface and is embedded in a self-produced extracellular matrix. In the biofilm 
bacterial cells adapt to environmental conditions and bacteria show increased (about 10-1000 
times) resistance against antimicrobial agents compared to planktonic bacteria.  
 There are several studies in the literature providing evidence of the EP, biofilm 
formation and QS inhibitory potential of natural, plant-derived and synthetic compounds, 
furthermore, they can potentiate the efficacy of antibiotics as well. In this study plant-derived 
compounds from Cleistochlamys kirkii (Benth) Oliv. (Annonaceae), synthesized fluorinated β-
diketo phosphorus ylides and selenocompounds were investigated. C. kirkii is an African 
medicinal plant traditionally used in Mozambique for the treatment of wound infections, 
tuberculosis, rheumatism and based on preliminary studies C. kirkii derivatives have 
antimicrobial activity. The EP modulating activity of phosphorus ylides has already been 
described regarding the ATP-binding cassette subfamily B member (ABCB1) pump of 
multidrug resistant (MDR) mouse T-lymphoma cells. Furthermore, selenium is an important 
trace element, which plays a role in the prevention of inflammatory diseases and cancer and 
selenium-containing compounds have a broad antimicrobial spectrum. 
 The spread of AMR is a global challenge and to overcome this problem the combination 
therapy could be a solution (antibiotic plus adjuvants: for example efflux pump inhibitor (EPI)) 
in order to improve the efficacy of antibacterial therapy, prevent the emergence of MDR 
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bacteria and decrease the costs of therapy. However, this requires the discovery of new efflux 
pump inhibitors that is a major challenge for drug development. 
 
2. AIMS OF THE STUDY 
 
 The aim of our study was to investigate the resistance modifying activity of bioactive 
compounds of C. kirkii, synthesized fluorinated β-diketo phosphorus ylides and 
selenocompounds on Gram-positive and Gram-negative model bacterial strains. 
The main goals of the study were the following: 
1. Determination of the antibacterial activity of the compounds (five natural compounds, 
ten fluorinated β-diketo phosphorus ylides and eleven selenocompounds) on Gram-
positive and Gram-negative strains by microdilution method. 
2. Investigation of the EP inhibitory effect of the compounds (five natural compounds, ten 
fluorinated β-diketo phosphorus ylides and eleven selenocompounds) on Gram-positive 
and Gram-negative strains using real-time ethidium bromide (EB) accumulation assay. 
3. Evaluation of the EP inhibitory effect of eleven selenocompounds on Gram-negative 
wild type Salmonella enterica serovar Typhimurium SL1344 strain expressing the 
AcrAB-TolC EP and its AcrB mutant L644 strain using EB efflux assay. 
4. Determination of the anti-biofilm activity of eleven selenocompounds on Gram-
negative, biofilm producing S. Typhimurium 14028s strain using crystal violet (CV).  
5. Characterization of the activity of five natural compounds of C. kirkii as adjuvants in 
the presence of tetracycline (TET) and ciprofloxacin (CIP) on Staphylococcus aureus 
ATCC 25923 and S. aureus 27213 strains by checkerboard method. 
6. Evaluation of the adjuvant role of eleven selenocompounds on Escherichia coli AG100 
strain by a two-fold broth microdilution method in the presence of TET and CIP. 
7. QS inhibition analysis of five natural compounds of C. kirkii and ten fluorinated β-
diketo phosphorus ylides using the sensor strain Chromobacterium violaceum 026 and 
the N-acyl-homoserine lactone (AHL) producer strain Enterobacter cloacae 31298 by 
agar diffusion method. 
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8. Monitoring the changes in relative gene expression of efflux (norA, mepA, acrA, acrB), 
antibiotic resistance (marR) and QS (sdiA) genes in the presence of the most effective 
EPIs investigated in this study (natural compounds isolated from C. kirkii, fluorinated 
β-diketo phosphorus ylides and selenocompounds) by reverse transcriptase quantitative 
polymerase chain reaction (RT-qPCR). 
3. MATERIALS AND METHODS 
 
3.1. Compounds 
 Five natural compounds (CK1-5) were isolated from the methanol extract of the root 
barks of C. kirkii (Benth) Oliv. (Annonaceae): triterpene polycarpol (CK1), C-benzylated 
flavanones chamanetin (CK2), isochamanetin (CK3), dichamanetin (CK4) and the heptane 
derivative acetylmelodorinol (CK5) were kindly provided by Prof. Dr. Maria-José U. Ferreira 
(Universidade de Lisboa, Lisbon, Portugal). The stock solutions (in 10 mM concentration) of 
compounds were prepared in dimethyl sulfoxide (DMSO). 
 Ten synthesized fluorinated β-diketo phosphorus ylides (P-ylides; PY1-10) were kindly 
provided by Prof. Dr. Masami Kawase (Matsuyama University, Matsuyama, Japan). The stock 
solutions (in 10 mg/mL concentration) of compounds were prepared in DMSO. 
 Eleven selenocompounds including a cyclic selenoanhydride (EDA1), heteroaryl 
selenoesters (EDA2-3) and aryl selenoesters (EDA4-11) were kindly provided by Dr. Enrique 
Domínguez-Álvarez (Consejo Superior de Investigaciones Científicas, Madrid, Spain) and 
Prof. Dr. Carmen Sanmartín (University of Navarra, Pamplona, Spain). The stock solutions (in 
10 mM concentration) of compounds were prepared in DMSO. 
 
3.2. Bacterial strains 
 Wild-type E. coli K-12 AG100 strain [argE3 thi-1 rpsL xyl mtl Δ(gal-uvrB) supE44], 
expressing the AcrAB-TolC EP at its basal level and its AcrAB-TolC deleted mutant E. coli 
AG100 A strain were used in the study. These strains were kindly provided by Prof. Dr. Hiroshi 
Nikaido (University of California, Berkeley, CA, USA). Wild-type S. Typhimurium SL1344 
and its acrB gene inactivated mutant S. Typhimurium strain (L644), furthermore, the biofilm 
producing S. Typhimurium 14028s strain were used in the study. These strains were kindly 
provided by Dr. Jessica M. A. Blair (University of Birmingham, Birmingham, United 
Kingdom).  
 S. aureus ATCC 25923, was used as the methicillin susceptible reference strain, and the 
methicillin and ofloxacin resistant S. aureus 272123 clinical isolate, was kindly provided by 
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Prof. Dr. Leonard Amaral (Institute of Hygiene and Tropical Medicine, Lisbon, Portugal). In 
addition, Enterococcus faecalis ATCC 29212 strain was used in the assays.  
 For quorum sensing tests, the following strains were used: C. violaceum 026 (CV026) 
as sensor strain and E. cloacae 31298 as AHL producer strain (a clinical isolate from a wound). 
3.3. Determination of minimum inhibitory concentrations by microdilution method 
 The minimum inhibitory concentrations (MICs) of all tested compounds were 
determined according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. The 
solvent DMSO had no antibacterial effect. 
3.4. Real-time accumulation assay by Roche LightCycler real-time thermocycler 
 The activity of compounds isolated from C. kirkii (CK1-5), P-ylides (PY1-10) and 
selenocompounds (EDA1-11) on the real-time accumulation of EB was assessed by the 
automated EB method using a LightCycler real-time thermocycler (LightCycler 1.5, Roche, 
Indianapolis, USA). Briefly, an aliquot of an overnight culture of S. aureus strains (ATCC 
25923 and MRSA 272123) in tryptic soy broth (TSB) medium was transferred to fresh TSB 
medium, and it was incubated until it reached an optical density (OD) of 0.6 at 600 nm. In case 
of E. coli AG100 and AG100 A, the medium used in the assay was LB broth. The cells were 
washed with phosphate buffered saline (PBS) and the compounds were added individually at 
different concentrations at ½ MIC, ⅓ MIC, ¼ MIC or ⅕ MIC (in double concentrated form) to 
the EB solution in PBS. In case of S. aureus strains, the concentration of EB was 0.5 μg/mL, 
for E. coli AG100 1 μg/mL, and in case of E. coli AG100 A it was 0.25 μg/mL. Then, 10 μL of 
the EB solution containing the compound were transferred into standard glass capillary tubes 
of 20 µL maximum volume (Roche, Indianapolis, USA), and 10 μL of bacterial suspension 
(OD of 0.6 at 600 nm) were added to the capillaries and the fluorescence was monitored at the 
FL-2 channel in every minute on a real-time basis. 
 From the real-time data, the activity of the compounds, namely the relative fluorescence 
index (RFI) of the last time point (minute 30) of the EB accumulation assay, was calculated 




Where RFtreated is the relative fluorescence (RF) at the last time point of EB retention curve in 










curve of the untreated control having the solvent control (DMSO). Verapamil was applied as a 
positive control on Gram-positive strains and promethazine (PMZ) was used on Gram-negative 
strains. 
3.5. Efflux assay using ethidium bromide 
 The activity of selenocompounds (EDA1-11) on the efflux of EB was determined on 
wild type (SL1344) and acrB gene inactivated (L644) S. Typhimurium strains. Briefly, an 
aliquot of an overnight culture of S. Typhimurium strain in Luria-Bertani (LB) medium was 
transferred to fresh LB medium, and it was incubated until it reached an OD of 0.4 at 600 nm. 
The cultures were washed in 20 mM potassium phosphate buffer (PPB) with 1 mM MgCl2 and 
the OD was adjusted to 0.2 at 600 nm. 100 μM of carbonyl cyanide m-chlorophenyl hydrazone 
(CCCP) was added to de-energize the cells and therefore EB was added at 50 μg/mL 
concentration. The cultures were incubated at 23°C with shaking at 150 rpm for 1 h. After the 
incubation period the cultures were centrifuged, and the pellet was re-suspended in 20 mM PPB 
with 1 mM MgCl2 and 5% glucose to energize the cells. Following energization, 200 µL of the 
bacterial culture were transferred into black 96-well microtiter plate (Corning, Amsterdam) 
containing the compounds at 50 µM (½ MIC) and the fluorescence of EB was measured over 2 
hours at excitation and emission wavelengths of 530 and 600 nm, respectively, using a 
FLUOstar Optima plate reader (BMG Labtech, United Kingdom). During the evaluation the 
exact time was determined when the fluorescence dropped by 25% and 50% of the starting 
value. CCCP was applied as a positive control and DMSO was used as a negative control. 
3.6. Measuring biofilm formation using crystal violet  
 The biofilm forming ability of S. Typhimurium 14028s strain was studied in 96-well 
microtiter plates using LB broth without salt in the presence of selenocompounds (EDA1-11). 
Initially, overnight cultures were diluted to an OD of 0.1 at 600 nm and then added to each well 
with the exception of the medium control wells and compounds were added at 50 µM (½ MIC) 
concentration. The final volume was 200 μL in each well. Plates were incubated at 30°C for 48 
h with gentle agitation (100 rpm). After the incubation period the medium was discarded, and 
the plate was washed with tap water. 200 μL CV (0.1% [v/v]) was added to the wells and 
incubated for 15 minutes at room temperature. CV was removed from the wells and the plate 
was washed again with tap water. 200 μL of 70% ethanol was added to each well and the biofilm 
formation was determined by measuring the OD at 600 nm using a FLUOstar Optima plate 
reader. The anti-biofilm effect of selenocompounds was expressed in the percentage (%) of 
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decrease in biofilm formation. The results were analyzed using t-test and p-values of <0.05 
were considered significant. 
3.7. Interaction between antibiotics and resistance modifiers using checkerboard method 
 The combined effect of chamanetin (CK2) and dichamanetin (CK4) and antibiotics 
(TET and CIP) on the growth inhibition of S. aureus ATCC 25923 and resistant S. aureus 
272123 strains was evaluated by checkerboard method. Two-fold serial dilutions of antibiotics 
were prepared in Mueller Hinton (MH) broth on the horizontal rows of microtiter plate and then 
cross-diluted vertically by two-fold serial dilutions of the compounds. After the dilution of an 
overnight culture, bacterial cells were re-suspended in MH medium containing 1×104 cells and 
distributed into each well. The plates were incubated for 18 h at 37°C. The cell growth rate was 
determined after MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
staining. The combination index (CI) values at 90% growth inhibition (ED90) were determined 
by CompuSyn software. CI values were calculated by means of the median-effect equation, 
where CI < 1, CI = 1 and CI > 1 represent synergism, an additive effect (or no interaction) and 
antagonism, respectively. 
3.8. Interaction between antibiotics and resistance modifiers using minimum inhibitory 
concentration reduction assay 
 The chemosensitizing effect of the selenocompounds (EDA1-11) was evaluated by the 
determination of the MIC values of the antibiotics (TET and CIP), in the presence of sub-
inhibitory concentrations of the compounds (½ MIC) in E. coli AG100 strain by a two-fold 
broth microdilution method in the 96-well plates, using serial dilutions of TET and CIP. 10-4 
dilution of an overnight bacterial culture in 50 µL of MH was then added to each well, with the 
exception of the medium control wells. The plates were then incubated at 37°C for 18 h. MIC 
values of the antibiotics and their combination with the tested compounds were determined by 
naked eyes. 
3.9. Assay for quorum sensing inhibition 
 Modified LB agar (prepared from yeast extract 5 g/L, tryptone 10 g/L, NaCl 10 g/L, 
K2HPO4 1 g/L, MgSO4 x 7H2O 0.3 g/L, FeNaEDTA 36 mg/L and agar 20 g/L) was used for 
these experiments. The sensor strain C. violaceum 026 and the AHL producer strain E. cloacae 
31298 were inoculated as parallel lines and incubated at room temperature (20C) for 24–48 h. 
Filter paper discs were impregnated with 10 μL of stock solutions (10 mM or 10 mg/mL) of the 
CK and PY compounds in DMSO. The discs were placed between the parallel lines of the 
sensor and the AHL producer strains on the surface of the nutrient agar. The plates were 
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incubated at room temperature for another 24–48 h, and the interactions between the strains and 
compounds were evaluated for the reduction in the size of the zone of pigment production and 
the zone of growth inhibition of the affected strains, in millimeters. PMZ was applied as a 
positive control. 
3.10. Expression analyses of genes by RT-qPCR reaction 
 E. coli AG100 strain was cultured in LB broth, S. aureus ATCC 25923 and MRSA 
272123 strains were cultured in TSB broth. On the day of RNA isolation, the compounds were 
added to the bacterial suspension at 50 µM (for EDA1, -4, -7), 50 µg/mL (for PY2, -4, -5), 5 
µM (for CK2) and 0.5 µM (for CK4) concentrations, which were incubated at 37°C. After 4 
hours (for CK2 and -4) or 4 and 18 hours (for PY2, -4, -5 and EDA1, -4, -7) of culturing, the 
total RNA was isolated in an RNase-free environment using NucleoSpin RNA kit (Macherey 
Nagel, Germany) according to the manufacturer’s instructions. The concentration of the 
extracted RNA templates was assessed by SmartSpecTM Plus Spectrophotometer at 260 nm 
(Bio-Rad, USA). 
 Expression of the efflux pump genes norA and mepA in the presence of chamanetin 
(CK2) and dichamanetin (CK4) was studied by reverse transcription of the total RNA of S. 
aureus ATCC 25923 and MRSA 272123 strains. The data obtained for gene targets were 
normalized against the S. aureus 16S ribosomal RNA gene measured in the same sample.  
 The effect of PY2, -4, -5 and EDA1, -4, -7 on the relative expression of the efflux pump 
(acrA, acrB), antibiotic resistance (marR) and QS (sdiA) genes were studied in E. coli AG100. 
The data obtained for gene targets were normalized against the E. coli house-keeping gene 
glyceraldehide-3-phosphate-dehydrogenase (gapdh) measured in the same sample.  
 Real-time quantification of the RNA templates by one-step RT-qPCR was performed in 
a CFX96 Touch real-time PCR detection system (Bio-Rad, USA) strictly adhered to the 
manufacturer’s recommendations of the SensiFASTTM SYBR No-ROX One-Step Kit (Bioline 
GmbH, Germany). The relative quantities of the mRNA of each gene of interest were 




4.1. In vitro antibacterial activity of compounds 
4.1.1. Bioactive compounds from C. kirkii 
 Concerning the antibacterial effect of the compounds, chamanetin (CK2) and 
dichamanetin (CK4) had a potent antibacterial effect on both S. aureus ATCC 25923 and S. 
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aureus 272123 strains. MIC of compound CK2 was 12.5 µM on reference S. aureus ATCC 
strain; however, the MIC of the methicillin and ofloxacin resistant strain was 25 µM. 
Compound CK4 was the most effective flavanone because its MIC on S. aureus ATCC 25923 
strain was 0.8 µM; furthermore, on the methicillin resistant strain it exhibited the MIC of 1.56 
µM. The compounds had no antibacterial effect on the Gram-negative E. coli AG100, AG100 
A, C. violaceum, and E. cloacae strains (MIC: >100 or 100 µM). 
4.1.2. Fluorinated β-diketo phosphorus ylides 
 Compounds PY1-10 did not have any antibacterial effect on the AcrAB-TolC-
expressing E. coli AG100, C. violaceum and E. cloacae strains and the AcrAB-TolC deleted E. 
coli AG100 A strain (MIC: >100 g/mL), except for ethyl-4,4,4-trifluoro-3-oxo-2-
(triphenylphosphoranylidene)butanoate (PY6), which had a mild effect on the EP deleted strain 
(MIC: 50 μg/mL). 
4.1.3. Selenocompounds 
 The ketone-containing selenoesters (EDA9–11) showed a potent antibacterial activity 
against the S. aureus ATCC 25923. The methylketone selenoester EDA9 was the most active 
compound with noteworthy MIC value (3.12 µM). The selenoanhydride EDA1 and the 
remaining selenoesters EDA2–8 evaluated were inactive as their MIC was equal or above 100 
µM on S. aureus ATCC 25923 strain. EDA9 showed antibacterial activity towards E. faecalis 
(MIC: 12.5 µM). The compounds had no antibacterial effect (MIC: 100 μM or >100 μM) on 
Gram-negative E. coli AG100, E. coli AG100 A, S. Typhimurium SL1344, acrB inactivated S. 
Typhimurium L644 and S. Typhimurium 14028s strains.  
4.2. Efflux pump inhibiting activity (accumulation assay) 
4.2.1. Bioactive compounds from C. kirkii 
 CK2 and CK4 had EP inhibiting activity compared to verapamil (RFI: 0.13) on the S. 
aureus ATCC 25923 strain, and the most active compound was CK2. However, compounds 
CK1–5 had no EP inhibitory activity on the methicillin resistant S. aureus strain at the 
concentrations applied in the assay. Concerning the inhibitory activity on Gram-negatives, 
triterpene polycarpol (CK1) and CK5 could inhibit the AcrAB-TolC system of E. coli AG100 
compared to PMZ (RFI: 0.15). Based on the real-time accumulation data, CK1–5 had no effect 
on the E. coli AG100 A strain lacking the AcrAB-TolC pump. 
4.2.2. Fluorinated β-diketo phosphorus ylides 
 The majority of the P-ylides were found to inhibit the AcrAB-TolC system of E. coli 
except PY3, PY7 and PY8, which had little or no effect on the intracellular EB accumulation 
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in both strains. Among the P-ylide series, PY2, -4, and -5 exhibited strong AcrAB-TolC pump 
inhibiting properties compared to the AcrAB-TolC pump deficient mutant strain. The most 
potent derivative was PY4 and its effect was more pronounced on the multidrug resistant E. 
coli strain compared to the pump deleted E. coli strain. 
4.2.3. Selenocompounds 
 EDA1 and EDA4 strongly inhibited the efflux mediated by AcrAB-TolC in E. coli 
AG100 compared to the positive control PMZ (RFI: 0.15). EDA7 and EDA9–11 caused 
moderate inhibitory action on the intracellular EB accumulation in E. coli AG100. 
Nevertheless, no EP inhibitory action was found in the E. coli AG100 A strain in case of 
selenocompounds (EDA1–11). 
4.3. Efflux pump inhibiting activity (efflux assay) 
 Each selenocompound showed a 25% and 50% decrease in fluorescence at an earlier 
time point, compared with positive control CCCP in S. Typhimurium SL1344. For the L644 
strain only EDA7 was able to prevent the efflux of EB more effectively than CCCP. 
4.4. Anti-biofilm activity of selenocompounds 
 Except compounds EDA6 and -11 all derivatives showed significant (>45%; p<0.05) or 
higher biofilm inhibition at 50 μM on S. Typhimurium 14028s. The most potent 
selenocompounds with anti-biofilm effect were EDA4 and -5 at 50 μM showing 75% and 73% 
of inhibition, respectively. 
4.5. Combined effects of chamanetin (CK2) and dichamanetin (CK4) with antibiotics 
 The combined effect of TET or CIP and compounds CK2 or CK4 on S. aureus ATCC 
25923 resulted in synergism. On the methicillin resistant S. aureus strain CK2 showed slight 
synergism with CIP. The interactions of CK4 with TET on the resistant S. aureus strain was 
synergism. 
4.6. Enhancement of the activity of antibiotics in the presence of selenocompounds 
 In the absence of selenocompounds, TET showed MIC value of 4.2 µM and CIP 
exhibited MIC of 0.02 µM. EDA9 potentiated the effect of TET (MIC: 2.1 µM) and CIP (MIC: 
0.01 µM), furthermore EDA10 reduced the MIC value of CIP by two-fold in E. coli strain.  
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4.7. Anti-quorum sensing activity 
4.7.1. Bioactive compounds from C. kirkii 
 Compounds CK1 (51 mm), -2 (50 mm), -4 (53 mm), and -5 (52 mm) were able to inhibit 
effectively the QS between C. violaceum 026 and E. cloacae compared to the positive control 
PMZ (46 mm). 
4.7.2. Fluorinated β-diketo phosphorus ylides 
 P-ylides were not able to inhibit the QS (inhibition zone: 0 mm) in the applied systems 
compared to the positive control PMZ. 
4.8. Relative expressions of genes related to antibiotic resistance and efflux pumps 
4.8.1. Bioactive compounds from C. kirkii 
 CK2 at 5 µM significantly up-regulated the expression of norA and mepA genes after 4 
h of exposure in S. aureus resistant strain. Compound CK4 at 0.5 µM also significantly up-
regulated both efflux pump genes after 4 h of exposure in S. aureus 272123. In S. aureus ATCC 
25923 strain, the expression level of the mepA gene was not influenced. Nevertheless, the norA 
gene was significantly up-regulated by compounds CK2 at 5 µM and CK4 at 0.5 µM. 
4.8.2. Fluorinated β-diketo phosphorus ylides 
 PY2 at 50 g/ml up-regulated all the genes studied after 4 h of exposure, however, after 
18 h the gene expression returned to basal levels. PY4 also significantly up-regulated the 
secondary resistance-nodulation-division family (RND) transporter gene acrB after 4 h and 18 
h exposures as well. PY5 up-regulated the expression levels of acrA and acrB after 4 h. 
4.8.3. Selenocompounds 
 EDA1 at 50 μM significantly up-regulated acrB, marR and sdiA genes studied after 4 h 
of exposure, however, after 18 h, the expression of acrB gene returned to basal level and the 
marR and sdiA genes increased significantly. EDA4 up-regulated the expression of acrB, marR 
and sdiA after 4 h although after 18 h the expression levels of acrB and marR genes decreased. 
The QS gene sdiA was significantly up-regulated after 18h. EDA7 also significantly up-
regulated marR after 4 h and 18 h exposures. After 18 h the RND transporter subunit genes 
(acrA, acrB) were significantly upregulated in the presence of EDA7. 
5. DISCUSSION 
 
 Multidrug resistance to antibiotics has become a serious problem in the treatment of 
infectious diseases. One of the most important mechanisms causing multidrug resistance is the 
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over-expression of EPs, whereby cells pump out toxic substances to the exterior of the cells. 
Infections caused by MDR bacteria lead to increased treatment costs and may result in fatal 
outcomes; consequently, it is a major challenge for drug development in order to discover new 
EPIs. 
The natural, plant-derived or synthetic compounds may represent a valuable source of new 
antibacterial agents because they can inhibit the growth of bacteria and the activity of bacterial 
efflux systems which indirectly prevent the formation of biofilm and the bacterial cell-to-cell 
communication system, furthermore, they can potentiate the efficacy of antibiotics as well.  
 The main goal of our study was to evaluate the antibacterial and multidrug resistance 
reversing effects of bioactive compounds from C. kirkii (CK1-5), fluorinated β-diketo 
phosphorus ylides (PY1-10) and selenocompounds (EDA1-11) in different bacterial models. 
The following methods were used in the studies: MIC determination, EB accumulation and 
efflux assay, checkerboard combination method, MIC reduction assay, biofilm, QS inhibitory 
test and RT-qPCR.  
5.1. Bioactive compounds from C. kirkii (CK1-5) 
 According to this study chamanetin (CK2) and dichamanetin (CK4) had the most 
pronounced antibacterial activity in case of methicillin sensitive and resistant S. aureus strains. 
Dichamanetin showed stronger effect than chamanetin, due to its higher lipophilic character 
resulting from the extra benzyl group at C‐6. In contrast to chamanetin, isochamanetin (CK3), 
differing only in the position of benzyl substituents, was inactive at the concentration tested. 
Thus, besides the importance of lipophilicity, the presence of a benzyl moiety at C‐8 appears to 
play a decisive role in the antibacterial activity of this type of compounds. In the combination 
assays, chamanetin and dichamanetin showed synergism with TET and CIP on the S. aureus 
reference strain. Furthermore, on the MRSA strain, chamanetin and dichamanetin, combined 
with TET and CIP, respectively, also showed synergism, which indicates that these compounds 
could be potential adjuvants in the therapy. Besides having an antibacterial effect, chamanetin 
and dichamanetin could inhibit the activity of EPs compared to the positive control on the S. 
aureus ATCC 25923. Furthermore, these compounds inhibited the QS between C. violaceum 
026 and E. cloacae 31298, and they caused over-expression of EP genes (norA and mepA) after 
4 h of exposure in the MRSA strain. The change in gene expression could be due to the stress 
response against chamanetin and dichamanetin because these compounds as potential noxious 
agents for S. aureus had to be extruded from the cytoplasm of the bacterium as soon as possible. 
This stress response can be the explanation for the up‐regulation of the EP genes after 4 h. 
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Chamanetin and dichamanetin influenced the expression of mepA gene in the MRSA strain, 
however, these compounds did not have any effect on the expression level of mepA in the 
reference S. aureus strain. The difference between the methicillin resistant S. aureus and 
methicillin susceptible S. aureus strains is due to the over-expression of the mepA gene in the 
resistant strain and it has low expression level in the reference strain. It has been demonstrated 
by other studies that the over-expression of EPs confers a fitness cost for the organism, for 
example, a resistant isolate over-expressing EPs shows reduced production of virulence 
determinants. In Gram‐negatives, compounds CK1–5 did not show antibacterial activity. The 
highly lipophilic polycarpol (CK1) inhibited the RND transporter AcrAB-TolC transport 
system in E. coli AG100 strain because it could increase the membrane permeability of bacteria. 
In contrast polycarpol had no EPI effect on the pump mutant E. coli AG100 A strain confirming 
that it may have a direct EPI effect on the AcrAB-TolC EP. In addition, apart from chamanetin 
and dichamanetin, polycarpol and acetylmelodorinol (CK5) were also able to inhibit effectively 
the bacterial communication. 
5.2. Fluorinated β-diketo phosphorus ylides (PY1-10) 
 In our previous study trifluoro-1-phenyl-2-(triphenylphosphoranylidene)butane-1,3-
dione (PY3), 4,4,5,5,5-pentafluoro-1-phenyl-2-(triphenylphosphoranylidene)pentane-1,3-
dione (PY7) and 4,4,5,5,6,6,6-heptafluoro-1-phenyl-2-(triphenylphosphoranylidene)hexane-
1,3-dione (PY8) have been shown to have activity against the EPs of cancer cells, but did not 
show any activity against the EPs of E. coli strains. The aim of the previous work was to 
examine the primary ATP-binding cassette subfamily B member (ABCB1) EP inhibitory effect 
of PY compounds in cancer cells, in the present study the compounds have been tested against 
the secondary AcrAB-TolC system in bacteria. It is important to note that ATP-binding cassette 
(ABC) transporters derive their energy from the hydrolysis of ATP, however, the AcrAB-TolC 
system is a proton motive force (PMF)-dependent multidrug efflux  
system. The most effective compounds in E. coli AG100 were  
1,1,1-trifluoro-3-oxo-1-methoxy-3-(triphenylphosphoranylidene)propane-2-one (PY2), 4,4,4-
trifluoro-3-oxo-2-(triphenylphosphoranylidene)butanal (PY4), and 1,1,1-trifluoro-3-
(triphenylphosphoranylidene)pentane-2,4-dione (PY5), which inhibited the AcrAB-TolC 
system and influenced the expression of the transporter genes acrA and acrB. In addition, 
although the compounds are not QS inhibitors, PY4 increased the expression of sdiA after 18 h 
exposure. The compounds in the R1 chain contain a trifluoromethyl ketone (COCF3) and the R
2 
chain is a methoxy (OMe; PY2), formyl (CHO; PY4), and acetyl (COMe; PY5) substituent. 
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Thus, some structurally related fluorinated β-diketo phosphorus ylides differ in their multidrug 
resistance reversal activities between cancer cells and bacterial strains, indicating that the 
compounds act differently as inhibitors of ABCB1 and AcrB efflux pumps because these pumps 
differ in their structure and energy source driving the pump (ATP and PMF, respectively).  
5.3. Selenocompounds (EDA1-11) 
 These novel selenocompounds were studied previously for anticancer and ABCB1 EP 
inhibitory activity in different cancer cells. According to the results on bacteria it was found 
that the ketone-containing selenoesters EDA9-11 showed antibacterial activity against S. 
aureus reference strain, furthermore the methylketone selenoester (EDA9) was effective on E. 
faecalis ATCC 29212. In the EB accumulation assay the cyclic selenoanhydride (EDA1) and 
the meta-substituted benzene selenodiester (EDA4) could inhibit the activity of the AcrAB-
TolC efflux pump system and they were more potent than the positive control PMZ in E. coli 
AG100. Methylketone selenoester significantly inhibited the efflux mechanism of wild-type S. 
Typhimurium SL1344 strain. EP inhibiting activity has been found for methoxycarbonylmethyl 
selenoester (EDA7) in the acrB mutant S. Typhimurium strain. From the results obtained in the 
EB efflux assay, it can be concluded that the same compounds had efflux pump inhibitory 
activity in the wild type and mutant S. Typhimurium strains as well. The similarities observed 
in the efflux assay of compounds mean that the derivatives do not directly inhibit the AcrAB-
TolC system of S. Typhimurium. 
Results showed that the meta-substituted benzene selenodiester (EDA4) and para-substituted 
benzene selenodiester (EDA5), which contain a phenyl ring, were the strongest inhibitors of 
biofilm formation in S. Typhimurium 14028s. EDA7-10 and the thiophene selenodiester 
(EDA2) and pyridine selenodiester (EDA3) also exerted a biofilm inhibiting activity higher 
than 50%. Methylketone selenoester reduced the MIC value of TET by 2-fold, furthermore this 
compound and chloro-substituted tert-butylketone selenoester potentiated the activity of TET 
and CIP on E. coli AG100. In the gene expression analysis, we observed that cyclic 
selenoanhydride, meta-substituted benzene selenodiester, and methoxycarbonylmethyl 
selenoester influenced the gene expression of resistance (and transporter) genes because these 
derivatives significantly up-regulated the marR gene after 4 and 18 h exposure, respectively. 
Furthermore, the QS gene sdiA was significantly up-regulated in the presence of cyclic 
selenoanhydride, after exposures of 4 h and 18 h. 
 According to the results these studies indicated that natural and synthetic compounds 
could be used as potential antibacterial agents alone or combination with antibiotics for the 
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treatment of infectious diseases. In addition, our studies are suggesting the importance of the 
substituent’s topology and moiety for the biological potency. In future studies, it will be 
necessary to design and analyze systematically more compounds and understand the structure-
activity relationships in order to develop potent resistance modifiers.  
6. NEW FINDINGS 
1. Bioactive compounds from Cleistochlamys kirkii 
•  Chamanetin (CK2) and dichamanetin (CK4) with a benzyl moiety at C-8 showed potent 
antibacterial effect against both Staphylococcus aureus ATCC 25923 reference and 
methicillin and ofloxacin resistant S. aureus 272123 strains. Moreover, dichamanetin 
proved to be the most active compound isolated from C. kirkii on these strains and has 
higher lipophilic character compared to chamanetin due to its extra benzyl group at C‐
6. Dichamanetin had synergistic activity with tetracycline and ciprofloxacin on S. 
aureus reference strain. Furthermore, dichamanetin showed synergism in combination 
with tetracycline on the methicillin and ofloxacin resistant S. aureus strain. 
•  Chamanetin and acetylmelodorinol (CK5) had potent efflux pump modulatory effects 
in S. aureus reference strain. Polycarpol (CK1) was the most effective efflux pump 
inhibitor on Escherichia coli AG100 inhibiting the AcrAB-TolC transporter system. All 
bioactive compounds of C. kirkii except isochamanetin (CK3) were able to inhibit 
effectively the bacterial quorum sensing system. 
2. Fluorinated β-diketo phosphorus ylides 
•  1,1,1-trifluoro-3-oxo-1-methoxy-3-(triphenylphosphoranylidene)propane-2-one 
(PY2), 4,4,4-trifluoro-3-oxo-2-(triphenylphosphoranylidene)butanal (PY4), and 1,1,1-
trifluoro-3-(triphenylphosphoranylidene)pentane-2,4-dione (PY5) inhibited directly the 
AcrAB-TolC efflux transporter in E. coli AG100 strain compared to the AcrAB-TolC 
pump mutant AG100 A strain. 
3. Selenocompounds 
•  Methylketone selenoester (EDA9) had antibacterial activity against the reference S. 
aureus ATCC 25923 and Enterococcus faecalis ATCC 29212 strains. 
•  Methylketone selenoester potentiated the effect of tetracycline and ciprofloxacin on the 
AcrAB-TolC expressing E. coli AG100 strain. 
•  Almost all selenocompounds showed potent anti-biofilm activity against Salmonella 
enterica serovar Typhimurium 14028s strain. 
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•  Cyclic selenoanhydride (EDA1), meta-substituted benzene selenodiester (EDA4) and 
methoxycarbonylmethyl selenoester (EDA7) were the most active inhibitors of the 
AcrAB-TolC system in E. coli AG100 strain. 
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